Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
and childhood, using mobile phone technology (mHealth) to measure diet and physical activity, and to deliver interventions promoting healthier lifestyles. The group also has a strong educational
-
responses to acute infections and cancer. Using a combination of several state-of-the-art single-cell technologies we strive to understand mechanisms underlying the generation, maintenance and consequences
-
) eligibility requirements at latest by the application deadline. It is your responsibility to certify eligibility by following the instructions on the web page Entry requirements (eligibility) for doctoral
-
-finance common resources (e.g., IT and an applied biostatistics group). The department is situated at campus Solna. Further information can be found at http://ki.se/en/meb The research group Our research
-
therapies for children with cancer. We do this by applying several different methods and techniques, including cell barcoding to study individual tumor subclones, state-of-the-art organoid technologies, high
-
targets. Proteomics involves various technologies and methods, such as mass spectrometry and bioinformatics. Our aim is to connect cancer proteome knowledge to genome and clinical data to improve
-
single cell biology technologies as well as antibody engineering, high dimensional flow cytometry and functional assays to understand molecular mechanisms of various autoimmune diseases. The candidate will
-
electrophysiological recordings or calcium imaging of neuronal activity. Optogenetics and tracing of neuronal networks are other central technologies. For more information see: https://ki.se/en/neuro/carlenlab
-
Aging Research Center (ARC), a division within NVS, is located at KI Campus Solna, Stockholm. It is a multidisciplinary academic environment, representing medicine (e.g., neurology, epidemiology
-
protocol making it possible to treat a broader range of tumor types. The doctoral student project and the duties of the doctoral student Adoptive Cell Therapy (ACT) with tumor infiltrating lymphocytes (TIL